Search

(EDGAR Online via COMTEX) -- 0000886163false00008861632024-11-072024-11-07 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ______________ FORM 8-K ______________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities [...]

(EDGAR Online via COMTEX) -- Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations This Quarterly Report on Form 10-Q contains 'forward-looking statements' as defined in [...]

(EDGAR Online via COMTEX) -- FALSE000100528605/2600010052862024-08-152024-08-15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act [...]

(EDGAR Online via COMTEX) -- Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations The following information should be read in conjunction with our unaudited condensed [...]

(EDGAR Online via COMTEX) -- Prospectus Supplement No. 3 Filed pursuant to Rule 424(b)(3) (to prospectus dated March 27, 2024) Registration No. 333-274863 [[Image Removed: img45989159_0.jpg]] DIANTHUS THERAPEUTICS, INC. 21,326,988 [...]

(EDGAR Online via COMTEX) -- Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations Forward Looking Statements This Quarterly Report on Form 10-Q and other written [...]

(EDGAR Online via COMTEX) -- Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations Caution: This discussion and analysis may contain predictions, estimates and other forward-looking [...]

(EDGAR Online via COMTEX) -- 0000886163false00008861632024-08-062024-08-06 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ______________ FORM 8-K ______________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities [...]

(EDGAR Online via COMTEX) -- Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations This Quarterly Report on Form 10-Q contains 'forward-looking statements' as defined in [...]

(EDGAR Online via COMTEX) -- 0000886163false00008861632024-07-152024-07-15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ______________ FORM 8-K ______________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities [...]

(EDGAR Online via COMTEX) -- 0000886163false00008861632024-07-082024-07-08 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ______________ FORM 8-K ______________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities [...]

(EDGAR Online via COMTEX) -- FALSE000100528600010052862024-06-282024-06-28 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act [...]

(EDGAR Online via COMTEX) -- 0000886163false00008861632024-06-272024-06-27 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ______________ FORM 8-K ______________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities [...]

(EDGAR Online via COMTEX) -- 0000886163false00008861632024-06-182024-06-18 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ______________ FORM 8-K ______________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities [...]

(EDGAR Online via COMTEX) -- 0000886163false00008861632024-05-292024-05-29 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ______________ FORM 8-K ______________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities [...]

(EDGAR Online via COMTEX) -- false000109897200010989722024-05-292024-05-29 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act [...]

(EDGAR Online via COMTEX) -- Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations The following information should be read in conjunction with our unaudited condensed [...]

(EDGAR Online via COMTEX) -- Prospectus Supplement No. 1 Filed pursuant to Rule 424(b)(3) (to prospectus dated March 27, 2024) Registration No. 333-274863 [[Image Removed: img17360008_0.jpg]] DIANTHUS THERAPEUTICS, INC. 21,326,988 [...]

(EDGAR Online via COMTEX) -- Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations The following discussion and analysis and the unaudited interim financial statements included [...]

(EDGAR Online via COMTEX) -- 0000886163false00008861632024-05-072024-05-07 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ______________ FORM 8-K ______________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities [...]

(EDGAR Online via COMTEX) -- false000109897200010989722024-05-062024-05-06 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act [...]

(EDGAR Online via COMTEX) -- 0000886163false00008861632024-05-062024-05-06 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ______________ FORM 8-K ______________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities [...]

(EDGAR Online via COMTEX) -- Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations This Quarterly Report on Form 10-Q contains 'forward-looking statements' as defined in [...]

(EDGAR Online via COMTEX) -- Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations You should read the following discussion and analysis of our financial condition [...]

(EDGAR Online via COMTEX) -- 0000886163false00008861632024-02-272024-02-27 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ______________ FORM 8-K ______________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities [...]

(EDGAR Online via COMTEX) -- Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations. You should read the following discussion and analysis in conjunction with Part [...]

(EDGAR Online via COMTEX) -- 0001708527false00017085272024-01-102024-01-10 UNITED STATES UNITED STATES UNITED STATES UNITED STATES UNITED STATES UNITED STATES UNITED STATES Date of report (Date of earliest event reported): January 10, [...]

(EDGAR Online via COMTEX) -- 0000886163false00008861632024-01-052024-01-05 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ______________ FORM 8-K ______________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities [...]

(EDGAR Online via COMTEX) -- 0000886163false00008861632023-11-292023-11-29 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ______________ FORM 8-K ______________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities [...]

(EDGAR Online via COMTEX) -- 0001708527false00017085272023-11-202023-11-200001708527us-gaap:AdditionalPaidInCapitalMemberus-gaap:IPOMember2022-01-012022-12-310001708527us-gaap:AdditionalPaidInCapitalMemberus-gaap:PrivatePlacementMember2021-01-012021-12-310001708527us-gaap:CommonClassAMemberus-gaap:CommonStockMemberus-gaap:IPOMember2022-01-012022-12-310001708527us-gaap:CommonClassBMemberus-gaap:CommonStockMemberus-gaap:PrivatePlacementMember2021-01-012021-12-310001708527us-gaap:CommonClassAMemberus-gaap:CommonStockMemberus-gaap:PrivatePlacementMember2021-01-012021-12-310001708527us-gaap:CommonClassAMemberus-gaap:CommonStockMember2022-01-012022-12-310001708527us-gaap:CommonClassAMemberus-gaap:CommonStockMember2021-01-012021-12-310001708527us-gaap:RetainedEarningsMember2022-12-310001708527us-gaap:AdditionalPaidInCapitalMember2022-12-310001708527us-gaap:RetainedEarningsMember2021-12-310001708527us-gaap:AdditionalPaidInCapitalMember2021-12-310001708527us-gaap:RetainedEarningsMember2020-12-310001708527us-gaap:AdditionalPaidInCapitalMember2020-12-310001708527us-gaap:CommonClassBMemberus-gaap:CommonStockMember2022-12-310001708527us-gaap:CommonClassAMemberus-gaap:CommonStockMember2022-12-310001708527us-gaap:CommonClassBMemberus-gaap:CommonStockMember2021-12-310001708527us-gaap:CommonClassAMemberus-gaap:CommonStockMember2021-12-310001708527us-gaap:CommonClassBMemberus-gaap:CommonStockMember2020-12-310001708527us-gaap:CommonClassAMemberus-gaap:CommonStockMember2020-12-310001708527azyo:StockOptionPlan2020Member2021-12-310001708527azyo:StockOptionPlan2020Member2021-01-012021-12-310001708527srt:ChiefExecutiveOfficerMemberus-gaap:EmployeeStockOptionMember2022-06-212022-06-210001708527azyo:StockOptionPlan2020Member2022-01-012022-12-310001708527us-gaap:EmployeeStockMember2022-12-310001708527azyo:PerformanceBasedOptionsMember2022-01-012022-12-310001708527us-gaap:EmployeeStockOptionMember2021-01-012021-12-310001708527srt:MinimumMemberus-gaap:EmployeeStockOptionMember2022-01-012022-12-310001708527srt:MaximumMemberus-gaap:EmployeeStockOptionMember2022-01-012022-12-310001708527us-gaap:RestrictedStockUnitsRSUMemberazyo:StockOptionPlan2020Member2022-12-310001708527azyo:PerformanceRestrictedStockUnitMember2022-12-310001708527us-gaap:RestrictedStockUnitsRSUMemberazyo:StockOptionPlan2020Member2021-12-310001708527srt:ChiefExecutiveOfficerMemberus-gaap:RestrictedStockUnitsRSUMember2022-06-212022-06-210001708527azyo:PerformanceRestrictedStockUnitMember2022-01-012022-12-310001708527us-gaap:RestrictedStockUnitsRSUMemberazyo:StockOptionPlan2020Member2022-01-012022-12-310001708527srt:ChiefExecutiveOfficerMemberazyo:TimeBasedRsuMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2022-06-212022-06-210001708527srt:ChiefExecutiveOfficerMemberazyo:TimeBasedRsuMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2022-06-212022-06-210001708527srt:ChiefExecutiveOfficerMemberazyo:TimeBasedOptionsMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2022-06-212022-06-210001708527srt:ChiefExecutiveOfficerMemberazyo:TimeBasedOptionsMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2022-06-212022-06-210001708527srt:MinimumMemberus-gaap:RestrictedStockUnitsRSUMember2022-01-012022-12-310001708527srt:MinimumMemberazyo:PerformanceRestrictedStockUnitMember2022-01-012022-12-310001708527srt:MaximumMemberus-gaap:RestrictedStockUnitsRSUMember2022-01-012022-12-310001708527srt:MaximumMemberazyo:PerformanceRestrictedStockUnitMember2022-01-012022-12-310001708527us-gaap:ShippingAndHandlingMember2022-01-012022-12-310001708527us-gaap:ShippingAndHandlingMember2021-01-012021-12-310001708527us-gaap:PrivatePlacementMember2022-12-080001708527us-gaap:CommonClassAMember2022-12-010001708527us-gaap:CommonClassBMemberus-gaap:PrivatePlacementMember2022-12-082022-12-080001708527us-gaap:CommonClassAMemberus-gaap:PrivatePlacementMember2022-12-082022-12-080001708527us-gaap:PrivatePlacementMember2022-12-082022-12-080001708527azyo:LicenseAgreementWithCookBiotechMember2021-01-012021-12-310001708527us-gaap:UnsecuredDebtMember2022-08-102022-08-100001708527srt:MinimumMemberus-gaap:OfficeEquipmentMember2022-01-012022-12-310001708527srt:MinimumMemberazyo:ProcessingAndResearchEquipmentMember2022-01-012022-12-310001708527srt:MaximumMemberus-gaap:OfficeEquipmentMember2022-01-012022-12-310001708527srt:MaximumMemberazyo:ProcessingAndResearchEquipmentMember2022-01-012022-12-310001708527us-gaap:ComputerEquipmentMember2022-01-012022-12-310001708527us-gaap:CommonClassAMember2022-12-012022-12-010001708527azyo:PaycheckProtectionProgramLoanCaresActMember2020-05-012020-05-310001708527azyo:MidcapLoanFacilityMember2019-07-012019-07-310001708527azyo:MidcapLoanFacilityMember2018-02-012018-02-280001708527azyo:MidcapLoanFacilityMember2017-12-012017-12-310001708527us-gaap:IPOMember2022-01-012022-12-310001708527us-gaap:PrivatePlacementMember2021-01-012021-12-310001708527srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2021-12-310001708527us-gaap:RetainedEarningsMember2022-01-012022-12-310001708527us-gaap:RetainedEarningsMember2021-01-012021-12-310001708527azyo:FibercelStrictLiabilityClaimsForDefectiveDesignDefectiveManufactureAndFailureToWarnMemberstpr:FL2022-01-012022-12-310001708527azyo:FibercelLossOfConsortiumMemberstpr:DE2022-01-012022-12-310001708527azyo:FibercelLitigationProductLabilityNegligenceBreachOfExpressAndImpliedWarrantiesAndPunitiveDamagesMemberstpr:IN2022-01-012022-12-310001708527azyo:NewAssetBasedRevolvingLoanFacilityMember2022-08-100001708527azyo:MidcapLoanFacilityMember2019-07-310001708527us-gaap:UnsecuredDebtMember2022-01-012022-12-310001708527azyo:May2017FinancingMember2022-01-012022-12-310001708527azyo:PaycheckProtectionProgramLoanCaresActMember2021-09-012021-09-300001708527us-gaap:CustomerRelationshipsMember2022-01-012022-12-310001708527azyo:AcquiredProductsMember2022-01-012022-12-310001708527us-gaap:CustomerRelationshipsMember2022-12-310001708527azyo:AcquiredProductsMember2022-12-310001708527us-gaap:CustomerRelationshipsMember2021-12-310001708527azyo:AcquiredProductsMember2021-12-310001708527us-gaap:FairValueInputsLevel3Memberazyo:RevenueInterestObligationMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001708527us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001708527azyo:RevenueInterestObligationMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001708527us-gaap:FairValueMeasurementsRecurringMember2022-12-310001708527us-gaap:FairValueInputsLevel3Memberazyo:RevenueInterestObligationMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001708527us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001708527azyo:RevenueInterestObligationMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001708527us-gaap:FairValueMeasurementsRecurringMember2021-12-310001708527azyo:RevenueInterestObligationMember2022-12-310001708527azyo:RevenueInterestObligationMember2021-12-310001708527azyo:RevenueInterestObligationMember2020-12-310001708527us-gaap:EmployeeStockOptionMemberazyo:StockOptionPlan2020Member2022-01-012022-12-310001708527us-gaap:EmployeeStockOptionMemberazyo:StockOptionPlan2020Member2022-12-310001708527us-gaap:RestrictedStockUnitsRSUMember2022-12-310001708527azyo:SWKLoanFacilityMember2023-11-082023-11-080001708527azyo:MidcapCreditFacilityMember2022-08-102022-08-100001708527us-gaap:DiscontinuedOperationsHeldforsaleMemberazyo:OrthobiologicsBusinessMember2023-09-172023-09-170001708527azyo:MidcapCreditFacilityMember2017-05-310001708527azyo:SWKLoanFacilityMember2022-08-102022-12-310001708527azyo:MidcapCreditFacilityMember2022-08-012022-08-090001708527azyo:MidcapCreditFacilityMember2022-07-012022-07-310001708527azyo:MidcapCreditFacilityMember2022-01-012022-06-300001708527azyo:MidcapLoanFacilityMember2021-01-012022-08-090001708527azyo:MidcapCreditFacilityMember2021-01-012021-12-310001708527us-gaap:UnsecuredDebtMember2017-12-310001708527azyo:MidcapLoanFacilityMember2017-05-310001708527azyo:TermLoanFacilityMember2022-12-310001708527srt:MinimumMemberazyo:SWKLoanFacilityMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember2022-08-102022-08-100001708527azyo:MidcapLoanFacilityMemberus-gaap:LondonInterbankOfferedRateLIBORMember2017-05-312017-05-310001708527azyo:MidcapCreditFacilityMemberus-gaap:LondonInterbankOfferedRateLIBORMember2017-05-312017-05-310001708527azyo:SurgalignHoldingsIncMemberazyo:ViboneExclusivityAgreementMember2018-08-310001708527us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberazyo:ViboneExclusivityAgreementMember2022-01-012022-12-310001708527us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberazyo:ViboneExclusivityAgreementMember2021-01-012021-12-310001708527us-gaap:CommonClassBMember2022-12-310001708527us-gaap:CommonClassAMember2022-12-310001708527us-gaap:CommonClassBMember2021-12-310001708527us-gaap:CommonClassAMember2021-12-310001708527azyo:StockOptionPlan2020Member2022-12-310001708527azyo:StockOptionPlan2020Member2020-10-0700017085272020-12-310001708527us-gaap:CustomerRelationshipsMember2017-05-310001708527azyo:AcquiredProductsMember2017-05-310001708527us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-12-310001708527us-gaap:EmployeeStockOptionMember2022-01-012022-12-310001708527azyo:ClassCommonStockWarrantsMember2022-01-012022-12-310001708527us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-12-310001708527us-gaap:EmployeeStockOptionMember2021-01-012021-12-310001708527us-gaap:SellingAndMarketingExpenseMember2022-01-012022-12-310001708527us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-12-310001708527us-gaap:GeneralAndAdministrativeExpenseMember2022-01-012022-12-310001708527us-gaap:CostOfSalesMember2022-01-012022-12-310001708527us-gaap:SellingAndMarketingExpenseMember2021-01-012021-12-310001708527us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-12-310001708527us-gaap:GeneralAndAdministrativeExpenseMember2021-01-012021-12-310001708527us-gaap:CostOfSalesMember2021-01-012021-12-310001708527us-gaap:AdditionalPaidInCapitalMember2022-01-012022-12-310001708527us-gaap:AdditionalPaidInCapitalMember2021-01-012021-12-310001708527us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberazyo:ViboneExclusivityAgreementMember2022-12-310001708527us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberazyo:ViboneExclusivityAgreementMember2021-12-310001708527srt:MaximumMemberazyo:SWKLoanFacilityMember2022-08-102022-08-100001708527srt:ChiefExecutiveOfficerMemberazyo:PerformanceRestrictedStockUnitMember2022-06-212022-06-210001708527srt:ChiefExecutiveOfficerMemberazyo:PerformanceBasedOptionsMember2022-06-212022-06-210001708527srt:ChiefExecutiveOfficerMemberus-gaap:RestrictedStockUnitsRSUMember2022-06-210001708527srt:ChiefExecutiveOfficerMemberus-gaap:EmployeeStockOptionMember2022-06-210001708527srt:ChiefExecutiveOfficerMemberazyo:TimeBasedOptionsMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2022-06-210001708527us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-12-310001708527us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-12-310001708527azyo:SWKLoanFacilityMember2023-11-080001708527azyo:LigandPharmaceuticalsMember2017-05-012017-05-310001708527azyo:LigandPharmaceuticalsMemberazyo:WhenCumulativeSalesOfProductsExceed300.0Member2017-05-310001708527azyo:LigandPharmaceuticalsMemberazyo:WhenCumulativeSalesOfProductsExceed100.0Member2017-05-310001708527azyo:LigandPharmaceuticalsMember2017-05-310001708527azyo:LigandPharmaceuticalsMember2017-05-312017-05-310001708527srt:MinimumMember2022-01-012022-12-310001708527srt:MaximumMember2022-01-012022-12-310001708527us-gaap:OfficeEquipmentMember2022-12-310001708527us-gaap:LeaseholdImprovementsMember2022-12-310001708527us-gaap:ComputerEquipmentMember2022-12-310001708527azyo:ProcessingAndResearchEquipmentMember2022-12-310001708527us-gaap:OfficeEquipmentMember2021-12-310001708527us-gaap:LeaseholdImprovementsMember2021-12-310001708527us-gaap:ComputerEquipmentMember2021-12-310001708527azyo:ProcessingAndResearchEquipmentMember2021-12-310001708527azyo:LicenseAgreementWithCookBiotechMember2022-01-012022-12-310001708527azyo:LicenseAgreementWithCookBiotechMember2022-12-310001708527us-gaap:StateAndLocalJurisdictionMember2022-12-310001708527us-gaap:DomesticCountryMember2022-12-310001708527azyo:FibercelLitigationProductLabilityMember2022-12-310001708527azyo:ProductionFacilitiesMember2022-12-310001708527azyo:AdministrativeFacilityMember2022-12-310001708527azyo:AdministrativeAndResearchFacilityMember2022-12-310001708527azyo:RevenueInterestObligationMember2021-01-012021-12-310001708527azyo:WomenSHealthMember2022-01-012022-12-310001708527azyo:DeviceProtectionMember2022-01-012022-12-310001708527azyo:CardiovascularMember2022-01-012022-12-310001708527azyo:WomenSHealthMember2021-01-012021-12-310001708527azyo:DeviceProtectionMember2021-01-012021-12-310001708527azyo:CardiovascularMember2021-01-012021-12-310001708527us-gaap:OtherNonoperatingIncomeExpenseMember2022-01-012022-12-310001708527azyo:RevenueInterestObligationMember2022-01-012022-12-310001708527us-gaap:EmployeeStockOptionMember2022-01-012022-12-310001708527azyo:FormerPresidentAndChiefExecutiveOfficerMember2022-09-302022-09-300001708527srt:ChiefExecutiveOfficerMember2022-06-212022-06-210001708527us-gaap:EmployeeStockMember2022-01-012022-12-310001708527azyo:KeralinkInternationalMember2018-01-012018-12-310001708527us-gaap:DiscontinuedOperationsHeldforsaleMemberazyo:OrthobiologicsBusinessMember2022-01-012022-12-310001708527us-gaap:DiscontinuedOperationsHeldforsaleMemberazyo:OrthobiologicsBusinessMember2021-01-012021-12-310001708527us-gaap:DiscontinuedOperationsHeldforsaleMemberazyo:OrthobiologicsBusinessMember2021-12-310001708527us-gaap:DiscontinuedOperationsHeldforsaleMemberazyo:OrthobiologicsBusinessMember2022-12-310001708527us-gaap:DiscontinuedOperationsHeldforsaleMemberazyo:OrthobiologicsBusinessMember2023-09-1700017085272022-01-012022-12-3100017085272021-01-012021-12-3100017085272022-12-3100017085272021-12-310001708527azyo:SWKLoanFacilityMember2022-12-310001708527azyo:SWKLoanFacilityMember2022-08-100001708527azyo:MidcapLoanFacilityMember2022-08-102022-08-100001708527azyo:MidcapLoanFacilityMember2017-05-312017-05-310001708527azyo:SWKLoanFacilityMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember2022-08-102022-08-100001708527azyo:SWKLoanFacilityMember2022-08-102022-08-100001708527azyo:FibercelLitigationProductLabilityMember2022-01-012022-12-310001708527azyo:KeralinkInternationalMember2021-05-310001708527azyo:KeralinkInternationalMember2018-12-31iso4217:USDazyo:casexbrli:purexbrli:sharesiso4217:USDxbrli:sharesazyo:segment UNITED STATES 0001708527false00017085272023-11-202023-11-200001708527us-gaap:AdditionalPaidInCapitalMemberus-gaap:IPOMember2022-01-012022-12-310001708527us-gaap:AdditionalPaidInCapitalMemberus-gaap:PrivatePlacementMember2021-01-012021-12-310001708527us-gaap:CommonClassAMemberus-gaap:CommonStockMemberus-gaap:IPOMember2022-01-012022-12-310001708527us-gaap:CommonClassBMemberus-gaap:CommonStockMemberus-gaap:PrivatePlacementMember2021-01-012021-12-310001708527us-gaap:CommonClassAMemberus-gaap:CommonStockMemberus-gaap:PrivatePlacementMember2021-01-012021-12-310001708527us-gaap:CommonClassAMemberus-gaap:CommonStockMember2022-01-012022-12-310001708527us-gaap:CommonClassAMemberus-gaap:CommonStockMember2021-01-012021-12-310001708527us-gaap:RetainedEarningsMember2022-12-310001708527us-gaap:AdditionalPaidInCapitalMember2022-12-310001708527us-gaap:RetainedEarningsMember2021-12-310001708527us-gaap:AdditionalPaidInCapitalMember2021-12-310001708527us-gaap:RetainedEarningsMember2020-12-310001708527us-gaap:AdditionalPaidInCapitalMember2020-12-310001708527us-gaap:CommonClassBMemberus-gaap:CommonStockMember2022-12-310001708527us-gaap:CommonClassAMemberus-gaap:CommonStockMember2022-12-310001708527us-gaap:CommonClassBMemberus-gaap:CommonStockMember2021-12-310001708527us-gaap:CommonClassAMemberus-gaap:CommonStockMember2021-12-310001708527us-gaap:CommonClassBMemberus-gaap:CommonStockMember2020-12-310001708527us-gaap:CommonClassAMemberus-gaap:CommonStockMember2020-12-310001708527azyo:StockOptionPlan2020Member2021-12-310001708527azyo:StockOptionPlan2020Member2021-01-012021-12-310001708527srt:ChiefExecutiveOfficerMemberus-gaap:EmployeeStockOptionMember2022-06-212022-06-210001708527azyo:StockOptionPlan2020Member2022-01-012022-12-310001708527us-gaap:EmployeeStockMember2022-12-310001708527azyo:PerformanceBasedOptionsMember2022-01-012022-12-310001708527us-gaap:EmployeeStockOptionMember2021-01-012021-12-310001708527srt:MinimumMemberus-gaap:EmployeeStockOptionMember2022-01-012022-12-310001708527srt:MaximumMemberus-gaap:EmployeeStockOptionMember2022-01-012022-12-310001708527us-gaap:RestrictedStockUnitsRSUMemberazyo:StockOptionPlan2020Member2022-12-310001708527azyo:PerformanceRestrictedStockUnitMember2022-12-310001708527us-gaap:RestrictedStockUnitsRSUMemberazyo:StockOptionPlan2020Member2021-12-310001708527srt:ChiefExecutiveOfficerMemberus-gaap:RestrictedStockUnitsRSUMember2022-06-212022-06-210001708527azyo:PerformanceRestrictedStockUnitMember2022-01-012022-12-310001708527us-gaap:RestrictedStockUnitsRSUMemberazyo:StockOptionPlan2020Member2022-01-012022-12-310001708527srt:ChiefExecutiveOfficerMemberazyo:TimeBasedRsuMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2022-06-212022-06-210001708527srt:ChiefExecutiveOfficerMemberazyo:TimeBasedRsuMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2022-06-212022-06-210001708527srt:ChiefExecutiveOfficerMemberazyo:TimeBasedOptionsMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2022-06-212022-06-210001708527srt:ChiefExecutiveOfficerMemberazyo:TimeBasedOptionsMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2022-06-212022-06-210001708527srt:MinimumMemberus-gaap:RestrictedStockUnitsRSUMember2022-01-012022-12-310001708527srt:MinimumMemberazyo:PerformanceRestrictedStockUnitMember2022-01-012022-12-310001708527srt:MaximumMemberus-gaap:RestrictedStockUnitsRSUMember2022-01-012022-12-310001708527srt:MaximumMemberazyo:PerformanceRestrictedStockUnitMember2022-01-012022-12-310001708527us-gaap:ShippingAndHandlingMember2022-01-012022-12-310001708527us-gaap:ShippingAndHandlingMember2021-01-012021-12-310001708527us-gaap:PrivatePlacementMember2022-12-080001708527us-gaap:CommonClassAMember2022-12-010001708527us-gaap:CommonClassBMemberus-gaap:PrivatePlacementMember2022-12-082022-12-080001708527us-gaap:CommonClassAMemberus-gaap:PrivatePlacementMember2022-12-082022-12-080001708527us-gaap:PrivatePlacementMember2022-12-082022-12-080001708527azyo:LicenseAgreementWithCookBiotechMember2021-01-012021-12-310001708527us-gaap:UnsecuredDebtMember2022-08-102022-08-100001708527srt:MinimumMemberus-gaap:OfficeEquipmentMember2022-01-012022-12-310001708527srt:MinimumMemberazyo:ProcessingAndResearchEquipmentMember2022-01-012022-12-310001708527srt:MaximumMemberus-gaap:OfficeEquipmentMember2022-01-012022-12-310001708527srt:MaximumMemberazyo:ProcessingAndResearchEquipmentMember2022-01-012022-12-310001708527us-gaap:ComputerEquipmentMember2022-01-012022-12-310001708527us-gaap:CommonClassAMember2022-12-012022-12-010001708527azyo:PaycheckProtectionProgramLoanCaresActMember2020-05-012020-05-310001708527azyo:MidcapLoanFacilityMember2019-07-012019-07-310001708527azyo:MidcapLoanFacilityMember2018-02-012018-02-280001708527azyo:MidcapLoanFacilityMember2017-12-012017-12-310001708527us-gaap:IPOMember2022-01-012022-12-310001708527us-gaap:PrivatePlacementMember2021-01-012021-12-310001708527srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2021-12-310001708527us-gaap:RetainedEarningsMember2022-01-012022-12-310001708527us-gaap:RetainedEarningsMember2021-01-012021-12-310001708527azyo:FibercelStrictLiabilityClaimsForDefectiveDesignDefectiveManufactureAndFailureToWarnMemberstpr:FL2022-01-012022-12-310001708527azyo:FibercelLossOfConsortiumMemberstpr:DE2022-01-012022-12-310001708527azyo:FibercelLitigationProductLabilityNegligenceBreachOfExpressAndImpliedWarrantiesAndPunitiveDamagesMemberstpr:IN2022-01-012022-12-310001708527azyo:NewAssetBasedRevolvingLoanFacilityMember2022-08-100001708527azyo:MidcapLoanFacilityMember2019-07-310001708527us-gaap:UnsecuredDebtMember2022-01-012022-12-310001708527azyo:May2017FinancingMember2022-01-012022-12-310001708527azyo:PaycheckProtectionProgramLoanCaresActMember2021-09-012021-09-300001708527us-gaap:CustomerRelationshipsMember2022-01-012022-12-310001708527azyo:AcquiredProductsMember2022-01-012022-12-310001708527us-gaap:CustomerRelationshipsMember2022-12-310001708527azyo:AcquiredProductsMember2022-12-310001708527us-gaap:CustomerRelationshipsMember2021-12-310001708527azyo:AcquiredProductsMember2021-12-310001708527us-gaap:FairValueInputsLevel3Memberazyo:RevenueInterestObligationMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001708527us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001708527azyo:RevenueInterestObligationMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001708527us-gaap:FairValueMeasurementsRecurringMember2022-12-310001708527us-gaap:FairValueInputsLevel3Memberazyo:RevenueInterestObligationMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001708527us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001708527azyo:RevenueInterestObligationMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001708527us-gaap:FairValueMeasurementsRecurringMember2021-12-310001708527azyo:RevenueInterestObligationMember2022-12-310001708527azyo:RevenueInterestObligationMember2021-12-310001708527azyo:RevenueInterestObligationMember2020-12-310001708527us-gaap:EmployeeStockOptionMemberazyo:StockOptionPlan2020Member2022-01-012022-12-310001708527us-gaap:EmployeeStockOptionMemberazyo:StockOptionPlan2020Member2022-12-310001708527us-gaap:RestrictedStockUnitsRSUMember2022-12-310001708527azyo:SWKLoanFacilityMember2023-11-082023-11-080001708527azyo:MidcapCreditFacilityMember2022-08-102022-08-100001708527us-gaap:DiscontinuedOperationsHeldforsaleMemberazyo:OrthobiologicsBusinessMember2023-09-172023-09-170001708527azyo:MidcapCreditFacilityMember2017-05-310001708527azyo:SWKLoanFacilityMember2022-08-102022-12-310001708527azyo:MidcapCreditFacilityMember2022-08-012022-08-090001708527azyo:MidcapCreditFacilityMember2022-07-012022-07-310001708527azyo:MidcapCreditFacilityMember2022-01-012022-06-300001708527azyo:MidcapLoanFacilityMember2021-01-012022-08-090001708527azyo:MidcapCreditFacilityMember2021-01-012021-12-310001708527us-gaap:UnsecuredDebtMember2017-12-310001708527azyo:MidcapLoanFacilityMember2017-05-310001708527azyo:TermLoanFacilityMember2022-12-310001708527srt:MinimumMemberazyo:SWKLoanFacilityMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember2022-08-102022-08-100001708527azyo:MidcapLoanFacilityMemberus-gaap:LondonInterbankOfferedRateLIBORMember2017-05-312017-05-310001708527azyo:MidcapCreditFacilityMemberus-gaap:LondonInterbankOfferedRateLIBORMember2017-05-312017-05-310001708527azyo:SurgalignHoldingsIncMemberazyo:ViboneExclusivityAgreementMember2018-08-310001708527us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberazyo:ViboneExclusivityAgreementMember2022-01-012022-12-310001708527us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberazyo:ViboneExclusivityAgreementMember2021-01-012021-12-310001708527us-gaap:CommonClassBMember2022-12-310001708527us-gaap:CommonClassAMember2022-12-310001708527us-gaap:CommonClassBMember2021-12-310001708527us-gaap:CommonClassAMember2021-12-310001708527azyo:StockOptionPlan2020Member2022-12-310001708527azyo:StockOptionPlan2020Member2020-10-0700017085272020-12-310001708527us-gaap:CustomerRelationshipsMember2017-05-310001708527azyo:AcquiredProductsMember2017-05-310001708527us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-12-310001708527us-gaap:EmployeeStockOptionMember2022-01-012022-12-310001708527azyo:ClassCommonStockWarrantsMember2022-01-012022-12-310001708527us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-12-310001708527us-gaap:EmployeeStockOptionMember2021-01-012021-12-310001708527us-gaap:SellingAndMarketingExpenseMember2022-01-012022-12-310001708527us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-12-310001708527us-gaap:GeneralAndAdministrativeExpenseMember2022-01-012022-12-310001708527us-gaap:CostOfSalesMember2022-01-012022-12-310001708527us-gaap:SellingAndMarketingExpenseMember2021-01-012021-12-310001708527us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-12-310001708527us-gaap:GeneralAndAdministrativeExpenseMember2021-01-012021-12-310001708527us-gaap:CostOfSalesMember2021-01-012021-12-310001708527us-gaap:AdditionalPaidInCapitalMember2022-01-012022-12-310001708527us-gaap:AdditionalPaidInCapitalMember2021-01-012021-12-310001708527us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberazyo:ViboneExclusivityAgreementMember2022-12-310001708527us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberazyo:ViboneExclusivityAgreementMember2021-12-310001708527srt:MaximumMemberazyo:SWKLoanFacilityMember2022-08-102022-08-100001708527srt:ChiefExecutiveOfficerMemberazyo:PerformanceRestrictedStockUnitMember2022-06-212022-06-210001708527srt:ChiefExecutiveOfficerMemberazyo:PerformanceBasedOptionsMember2022-06-212022-06-210001708527srt:ChiefExecutiveOfficerMemberus-gaap:RestrictedStockUnitsRSUMember2022-06-210001708527srt:ChiefExecutiveOfficerMemberus-gaap:EmployeeStockOptionMember2022-06-210001708527srt:ChiefExecutiveOfficerMemberazyo:TimeBasedOptionsMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2022-06-210001708527us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-12-310001708527us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-12-310001708527azyo:SWKLoanFacilityMember2023-11-080001708527azyo:LigandPharmaceuticalsMember2017-05-012017-05-310001708527azyo:LigandPharmaceuticalsMemberazyo:WhenCumulativeSalesOfProductsExceed300.0Member2017-05-310001708527azyo:LigandPharmaceuticalsMemberazyo:WhenCumulativeSalesOfProductsExceed100.0Member2017-05-310001708527azyo:LigandPharmaceuticalsMember2017-05-310001708527azyo:LigandPharmaceuticalsMember2017-05-312017-05-310001708527srt:MinimumMember2022-01-012022-12-310001708527srt:MaximumMember2022-01-012022-12-310001708527us-gaap:OfficeEquipmentMember2022-12-310001708527us-gaap:LeaseholdImprovementsMember2022-12-310001708527us-gaap:ComputerEquipmentMember2022-12-310001708527azyo:ProcessingAndResearchEquipmentMember2022-12-310001708527us-gaap:OfficeEquipmentMember2021-12-310001708527us-gaap:LeaseholdImprovementsMember2021-12-310001708527us-gaap:ComputerEquipmentMember2021-12-310001708527azyo:ProcessingAndResearchEquipmentMember2021-12-310001708527azyo:LicenseAgreementWithCookBiotechMember2022-01-012022-12-310001708527azyo:LicenseAgreementWithCookBiotechMember2022-12-310001708527us-gaap:StateAndLocalJurisdictionMember2022-12-310001708527us-gaap:DomesticCountryMember2022-12-310001708527azyo:FibercelLitigationProductLabilityMember2022-12-310001708527azyo:ProductionFacilitiesMember2022-12-310001708527azyo:AdministrativeFacilityMember2022-12-310001708527azyo:AdministrativeAndResearchFacilityMember2022-12-310001708527azyo:RevenueInterestObligationMember2021-01-012021-12-310001708527azyo:WomenSHealthMember2022-01-012022-12-310001708527azyo:DeviceProtectionMember2022-01-012022-12-310001708527azyo:CardiovascularMember2022-01-012022-12-310001708527azyo:WomenSHealthMember2021-01-012021-12-310001708527azyo:DeviceProtectionMember2021-01-012021-12-310001708527azyo:CardiovascularMember2021-01-012021-12-310001708527us-gaap:OtherNonoperatingIncomeExpenseMember2022-01-012022-12-310001708527azyo:RevenueInterestObligationMember2022-01-012022-12-310001708527us-gaap:EmployeeStockOptionMember2022-01-012022-12-310001708527azyo:FormerPresidentAndChiefExecutiveOfficerMember2022-09-302022-09-300001708527srt:ChiefExecutiveOfficerMember2022-06-212022-06-210001708527us-gaap:EmployeeStockMember2022-01-012022-12-310001708527azyo:KeralinkInternationalMember2018-01-012018-12-310001708527us-gaap:DiscontinuedOperationsHeldforsaleMemberazyo:OrthobiologicsBusinessMember2022-01-012022-12-310001708527us-gaap:DiscontinuedOperationsHeldforsaleMemberazyo:OrthobiologicsBusinessMember2021-01-012021-12-310001708527us-gaap:DiscontinuedOperationsHeldforsaleMemberazyo:OrthobiologicsBusinessMember2021-12-310001708527us-gaap:DiscontinuedOperationsHeldforsaleMemberazyo:OrthobiologicsBusinessMember2022-12-310001708527us-gaap:DiscontinuedOperationsHeldforsaleMemberazyo:OrthobiologicsBusinessMember2023-09-1700017085272022-01-012022-12-3100017085272021-01-012021-12-3100017085272022-12-3100017085272021-12-310001708527azyo:SWKLoanFacilityMember2022-12-310001708527azyo:SWKLoanFacilityMember2022-08-100001708527azyo:MidcapLoanFacilityMember2022-08-102022-08-100001708527azyo:MidcapLoanFacilityMember2017-05-312017-05-310001708527azyo:SWKLoanFacilityMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember2022-08-102022-08-100001708527azyo:SWKLoanFacilityMember2022-08-102022-08-100001708527azyo:FibercelLitigationProductLabilityMember2022-01-012022-12-310001708527azyo:KeralinkInternationalMember2021-05-310001708527azyo:KeralinkInternationalMember2018-12-31iso4217:USDazyo:casexbrli:purexbrli:sharesiso4217:USDxbrli:sharesazyo:segment UNITED STATES 0001708527false00017085272023-11-202023-11-200001708527us-gaap:AdditionalPaidInCapitalMemberus-gaap:IPOMember2022-01-012022-12-310001708527us-gaap:AdditionalPaidInCapitalMemberus-gaap:PrivatePlacementMember2021-01-012021-12-310001708527us-gaap:CommonClassAMemberus-gaap:CommonStockMemberus-gaap:IPOMember2022-01-012022-12-310001708527us-gaap:CommonClassBMemberus-gaap:CommonStockMemberus-gaap:PrivatePlacementMember2021-01-012021-12-310001708527us-gaap:CommonClassAMemberus-gaap:CommonStockMemberus-gaap:PrivatePlacementMember2021-01-012021-12-310001708527us-gaap:CommonClassAMemberus-gaap:CommonStockMember2022-01-012022-12-310001708527us-gaap:CommonClassAMemberus-gaap:CommonStockMember2021-01-012021-12-310001708527us-gaap:RetainedEarningsMember2022-12-310001708527us-gaap:AdditionalPaidInCapitalMember2022-12-310001708527us-gaap:RetainedEarningsMember2021-12-310001708527us-gaap:AdditionalPaidInCapitalMember2021-12-310001708527us-gaap:RetainedEarningsMember2020-12-310001708527us-gaap:AdditionalPaidInCapitalMember2020-12-310001708527us-gaap:CommonClassBMemberus-gaap:CommonStockMember2022-12-310001708527us-gaap:CommonClassAMemberus-gaap:CommonStockMember2022-12-310001708527us-gaap:CommonClassBMemberus-gaap:CommonStockMember2021-12-310001708527us-gaap:CommonClassAMemberus-gaap:CommonStockMember2021-12-310001708527us-gaap:CommonClassBMemberus-gaap:CommonStockMember2020-12-310001708527us-gaap:CommonClassAMemberus-gaap:CommonStockMember2020-12-310001708527azyo:StockOptionPlan2020Member2021-12-310001708527azyo:StockOptionPlan2020Member2021-01-012021-12-310001708527srt:ChiefExecutiveOfficerMemberus-gaap:EmployeeStockOptionMember2022-06-212022-06-210001708527azyo:StockOptionPlan2020Member2022-01-012022-12-310001708527us-gaap:EmployeeStockMember2022-12-310001708527azyo:PerformanceBasedOptionsMember2022-01-012022-12-310001708527us-gaap:EmployeeStockOptionMember2021-01-012021-12-310001708527srt:MinimumMemberus-gaap:EmployeeStockOptionMember2022-01-012022-12-310001708527srt:MaximumMemberus-gaap:EmployeeStockOptionMember2022-01-012022-12-310001708527us-gaap:RestrictedStockUnitsRSUMemberazyo:StockOptionPlan2020Member2022-12-310001708527azyo:PerformanceRestrictedStockUnitMember2022-12-310001708527us-gaap:RestrictedStockUnitsRSUMemberazyo:StockOptionPlan2020Member2021-12-310001708527srt:ChiefExecutiveOfficerMemberus-gaap:RestrictedStockUnitsRSUMember2022-06-212022-06-210001708527azyo:PerformanceRestrictedStockUnitMember2022-01-012022-12-310001708527us-gaap:RestrictedStockUnitsRSUMemberazyo:StockOptionPlan2020Member2022-01-012022-12-310001708527srt:ChiefExecutiveOfficerMemberazyo:TimeBasedRsuMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2022-06-212022-06-210001708527srt:ChiefExecutiveOfficerMemberazyo:TimeBasedRsuMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2022-06-212022-06-210001708527srt:ChiefExecutiveOfficerMemberazyo:TimeBasedOptionsMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2022-06-212022-06-210001708527srt:ChiefExecutiveOfficerMemberazyo:TimeBasedOptionsMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2022-06-212022-06-210001708527srt:MinimumMemberus-gaap:RestrictedStockUnitsRSUMember2022-01-012022-12-310001708527srt:MinimumMemberazyo:PerformanceRestrictedStockUnitMember2022-01-012022-12-310001708527srt:MaximumMemberus-gaap:RestrictedStockUnitsRSUMember2022-01-012022-12-310001708527srt:MaximumMemberazyo:PerformanceRestrictedStockUnitMember2022-01-012022-12-310001708527us-gaap:ShippingAndHandlingMember2022-01-012022-12-310001708527us-gaap:ShippingAndHandlingMember2021-01-012021-12-310001708527us-gaap:PrivatePlacementMember2022-12-080001708527us-gaap:CommonClassAMember2022-12-010001708527us-gaap:CommonClassBMemberus-gaap:PrivatePlacementMember2022-12-082022-12-080001708527us-gaap:CommonClassAMemberus-gaap:PrivatePlacementMember2022-12-082022-12-080001708527us-gaap:PrivatePlacementMember2022-12-082022-12-080001708527azyo:LicenseAgreementWithCookBiotechMember2021-01-012021-12-310001708527us-gaap:UnsecuredDebtMember2022-08-102022-08-100001708527srt:MinimumMemberus-gaap:OfficeEquipmentMember2022-01-012022-12-310001708527srt:MinimumMemberazyo:ProcessingAndResearchEquipmentMember2022-01-012022-12-310001708527srt:MaximumMemberus-gaap:OfficeEquipmentMember2022-01-012022-12-310001708527srt:MaximumMemberazyo:ProcessingAndResearchEquipmentMember2022-01-012022-12-310001708527us-gaap:ComputerEquipmentMember2022-01-012022-12-310001708527us-gaap:CommonClassAMember2022-12-012022-12-010001708527azyo:PaycheckProtectionProgramLoanCaresActMember2020-05-012020-05-310001708527azyo:MidcapLoanFacilityMember2019-07-012019-07-310001708527azyo:MidcapLoanFacilityMember2018-02-012018-02-280001708527azyo:MidcapLoanFacilityMember2017-12-012017-12-310001708527us-gaap:IPOMember2022-01-012022-12-310001708527us-gaap:PrivatePlacementMember2021-01-012021-12-310001708527srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2021-12-310001708527us-gaap:RetainedEarningsMember2022-01-012022-12-310001708527us-gaap:RetainedEarningsMember2021-01-012021-12-310001708527azyo:FibercelStrictLiabilityClaimsForDefectiveDesignDefectiveManufactureAndFailureToWarnMemberstpr:FL2022-01-012022-12-310001708527azyo:FibercelLossOfConsortiumMemberstpr:DE2022-01-012022-12-310001708527azyo:FibercelLitigationProductLabilityNegligenceBreachOfExpressAndImpliedWarrantiesAndPunitiveDamagesMemberstpr:IN2022-01-012022-12-310001708527azyo:NewAssetBasedRevolvingLoanFacilityMember2022-08-100001708527azyo:MidcapLoanFacilityMember2019-07-310001708527us-gaap:UnsecuredDebtMember2022-01-012022-12-310001708527azyo:May2017FinancingMember2022-01-012022-12-310001708527azyo:PaycheckProtectionProgramLoanCaresActMember2021-09-012021-09-300001708527us-gaap:CustomerRelationshipsMember2022-01-012022-12-310001708527azyo:AcquiredProductsMember2022-01-012022-12-310001708527us-gaap:CustomerRelationshipsMember2022-12-310001708527azyo:AcquiredProductsMember2022-12-310001708527us-gaap:CustomerRelationshipsMember2021-12-310001708527azyo:AcquiredProductsMember2021-12-310001708527us-gaap:FairValueInputsLevel3Memberazyo:RevenueInterestObligationMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001708527us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001708527azyo:RevenueInterestObligationMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001708527us-gaap:FairValueMeasurementsRecurringMember2022-12-310001708527us-gaap:FairValueInputsLevel3Memberazyo:RevenueInterestObligationMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001708527us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001708527azyo:RevenueInterestObligationMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001708527us-gaap:FairValueMeasurementsRecurringMember2021-12-310001708527azyo:RevenueInterestObligationMember2022-12-310001708527azyo:RevenueInterestObligationMember2021-12-310001708527azyo:RevenueInterestObligationMember2020-12-310001708527us-gaap:EmployeeStockOptionMemberazyo:StockOptionPlan2020Member2022-01-012022-12-310001708527us-gaap:EmployeeStockOptionMemberazyo:StockOptionPlan2020Member2022-12-310001708527us-gaap:RestrictedStockUnitsRSUMember2022-12-310001708527azyo:SWKLoanFacilityMember2023-11-082023-11-080001708527azyo:MidcapCreditFacilityMember2022-08-102022-08-100001708527us-gaap:DiscontinuedOperationsHeldforsaleMemberazyo:OrthobiologicsBusinessMember2023-09-172023-09-170001708527azyo:MidcapCreditFacilityMember2017-05-310001708527azyo:SWKLoanFacilityMember2022-08-102022-12-310001708527azyo:MidcapCreditFacilityMember2022-08-012022-08-090001708527azyo:MidcapCreditFacilityMember2022-07-012022-07-310001708527azyo:MidcapCreditFacilityMember2022-01-012022-06-300001708527azyo:MidcapLoanFacilityMember2021-01-012022-08-090001708527azyo:MidcapCreditFacilityMember2021-01-012021-12-310001708527us-gaap:UnsecuredDebtMember2017-12-310001708527azyo:MidcapLoanFacilityMember2017-05-310001708527azyo:TermLoanFacilityMember2022-12-310001708527srt:MinimumMemberazyo:SWKLoanFacilityMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember2022-08-102022-08-100001708527azyo:MidcapLoanFacilityMemberus-gaap:LondonInterbankOfferedRateLIBORMember2017-05-312017-05-310001708527azyo:MidcapCreditFacilityMemberus-gaap:LondonInterbankOfferedRateLIBORMember2017-05-312017-05-310001708527azyo:SurgalignHoldingsIncMemberazyo:ViboneExclusivityAgreementMember2018-08-310001708527us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberazyo:ViboneExclusivityAgreementMember2022-01-012022-12-310001708527us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberazyo:ViboneExclusivityAgreementMember2021-01-012021-12-310001708527us-gaap:CommonClassBMember2022-12-310001708527us-gaap:CommonClassAMember2022-12-310001708527us-gaap:CommonClassBMember2021-12-310001708527us-gaap:CommonClassAMember2021-12-310001708527azyo:StockOptionPlan2020Member2022-12-310001708527azyo:StockOptionPlan2020Member2020-10-0700017085272020-12-310001708527us-gaap:CustomerRelationshipsMember2017-05-310001708527azyo:AcquiredProductsMember2017-05-310001708527us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-12-310001708527us-gaap:EmployeeStockOptionMember2022-01-012022-12-310001708527azyo:ClassCommonStockWarrantsMember2022-01-012022-12-310001708527us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-12-310001708527us-gaap:EmployeeStockOptionMember2021-01-012021-12-310001708527us-gaap:SellingAndMarketingExpenseMember2022-01-012022-12-310001708527us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-12-310001708527us-gaap:GeneralAndAdministrativeExpenseMember2022-01-012022-12-310001708527us-gaap:CostOfSalesMember2022-01-012022-12-310001708527us-gaap:SellingAndMarketingExpenseMember2021-01-012021-12-310001708527us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-12-310001708527us-gaap:GeneralAndAdministrativeExpenseMember2021-01-012021-12-310001708527us-gaap:CostOfSalesMember2021-01-012021-12-310001708527us-gaap:AdditionalPaidInCapitalMember2022-01-012022-12-310001708527us-gaap:AdditionalPaidInCapitalMember2021-01-012021-12-310001708527us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberazyo:ViboneExclusivityAgreementMember2022-12-310001708527us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberazyo:ViboneExclusivityAgreementMember2021-12-310001708527srt:MaximumMemberazyo:SWKLoanFacilityMember2022-08-102022-08-100001708527srt:ChiefExecutiveOfficerMemberazyo:PerformanceRestrictedStockUnitMember2022-06-212022-06-210001708527srt:ChiefExecutiveOfficerMemberazyo:PerformanceBasedOptionsMember2022-06-212022-06-210001708527srt:ChiefExecutiveOfficerMemberus-gaap:RestrictedStockUnitsRSUMember2022-06-210001708527srt:ChiefExecutiveOfficerMemberus-gaap:EmployeeStockOptionMember2022-06-210001708527srt:ChiefExecutiveOfficerMemberazyo:TimeBasedOptionsMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2022-06-210001708527us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-12-310001708527us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-12-310001708527azyo:SWKLoanFacilityMember2023-11-080001708527azyo:LigandPharmaceuticalsMember2017-05-012017-05-310001708527azyo:LigandPharmaceuticalsMemberazyo:WhenCumulativeSalesOfProductsExceed300.0Member2017-05-310001708527azyo:LigandPharmaceuticalsMemberazyo:WhenCumulativeSalesOfProductsExceed100.0Member2017-05-310001708527azyo:LigandPharmaceuticalsMember2017-05-310001708527azyo:LigandPharmaceuticalsMember2017-05-312017-05-310001708527srt:MinimumMember2022-01-012022-12-310001708527srt:MaximumMember2022-01-012022-12-310001708527us-gaap:OfficeEquipmentMember2022-12-310001708527us-gaap:LeaseholdImprovementsMember2022-12-310001708527us-gaap:ComputerEquipmentMember2022-12-310001708527azyo:ProcessingAndResearchEquipmentMember2022-12-310001708527us-gaap:OfficeEquipmentMember2021-12-310001708527us-gaap:LeaseholdImprovementsMember2021-12-310001708527us-gaap:ComputerEquipmentMember2021-12-310001708527azyo:ProcessingAndResearchEquipmentMember2021-12-310001708527azyo:LicenseAgreementWithCookBiotechMember2022-01-012022-12-310001708527azyo:LicenseAgreementWithCookBiotechMember2022-12-310001708527us-gaap:StateAndLocalJurisdictionMember2022-12-310001708527us-gaap:DomesticCountryMember2022-12-310001708527azyo:FibercelLitigationProductLabilityMember2022-12-310001708527azyo:ProductionFacilitiesMember2022-12-310001708527azyo:AdministrativeFacilityMember2022-12-310001708527azyo:AdministrativeAndResearchFacilityMember2022-12-310001708527azyo:RevenueInterestObligationMember2021-01-012021-12-310001708527azyo:WomenSHealthMember2022-01-012022-12-310001708527azyo:DeviceProtectionMember2022-01-012022-12-310001708527azyo:CardiovascularMember2022-01-012022-12-310001708527azyo:WomenSHealthMember2021-01-012021-12-310001708527azyo:DeviceProtectionMember2021-01-012021-12-310001708527azyo:CardiovascularMember2021-01-012021-12-310001708527us-gaap:OtherNonoperatingIncomeExpenseMember2022-01-012022-12-310001708527azyo:RevenueInterestObligationMember2022-01-012022-12-310001708527us-gaap:EmployeeStockOptionMember2022-01-012022-12-310001708527azyo:FormerPresidentAndChiefExecutiveOfficerMember2022-09-302022-09-300001708527srt:ChiefExecutiveOfficerMember2022-06-212022-06-210001708527us-gaap:EmployeeStockMember2022-01-012022-12-310001708527azyo:KeralinkInternationalMember2018-01-012018-12-310001708527us-gaap:DiscontinuedOperationsHeldforsaleMemberazyo:OrthobiologicsBusinessMember2022-01-012022-12-310001708527us-gaap:DiscontinuedOperationsHeldforsaleMemberazyo:OrthobiologicsBusinessMember2021-01-012021-12-310001708527us-gaap:DiscontinuedOperationsHeldforsaleMemberazyo:OrthobiologicsBusinessMember2021-12-310001708527us-gaap:DiscontinuedOperationsHeldforsaleMemberazyo:OrthobiologicsBusinessMember2022-12-310001708527us-gaap:DiscontinuedOperationsHeldforsaleMemberazyo:OrthobiologicsBusinessMember2023-09-1700017085272022-01-012022-12-3100017085272021-01-012021-12-3100017085272022-12-3100017085272021-12-310001708527azyo:SWKLoanFacilityMember2022-12-310001708527azyo:SWKLoanFacilityMember2022-08-100001708527azyo:MidcapLoanFacilityMember2022-08-102022-08-100001708527azyo:MidcapLoanFacilityMember2017-05-312017-05-310001708527azyo:SWKLoanFacilityMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember2022-08-102022-08-100001708527azyo:SWKLoanFacilityMember2022-08-102022-08-100001708527azyo:FibercelLitigationProductLabilityMember2022-01-012022-12-310001708527azyo:KeralinkInternationalMember2021-05-310001708527azyo:KeralinkInternationalMember2018-12-31iso4217:USDazyo:casexbrli:purexbrli:sharesiso4217:USDxbrli:sharesazyo:segment UNITED STATES 0001708527false00017085272023-11-202023-11-200001708527us-gaap:AdditionalPaidInCapitalMemberus-gaap:IPOMember2022-01-012022-12-310001708527us-gaap:AdditionalPaidInCapitalMemberus-gaap:PrivatePlacementMember2021-01-012021-12-310001708527us-gaap:CommonClassAMemberus-gaap:CommonStockMemberus-gaap:IPOMember2022-01-012022-12-310001708527us-gaap:CommonClassBMemberus-gaap:CommonStockMemberus-gaap:PrivatePlacementMember2021-01-012021-12-310001708527us-gaap:CommonClassAMemberus-gaap:CommonStockMemberus-gaap:PrivatePlacementMember2021-01-012021-12-310001708527us-gaap:CommonClassAMemberus-gaap:CommonStockMember2022-01-012022-12-310001708527us-gaap:CommonClassAMemberus-gaap:CommonStockMember2021-01-012021-12-310001708527us-gaap:RetainedEarningsMember2022-12-310001708527us-gaap:AdditionalPaidInCapitalMember2022-12-310001708527us-gaap:RetainedEarningsMember2021-12-310001708527us-gaap:AdditionalPaidInCapitalMember2021-12-310001708527us-gaap:RetainedEarningsMember2020-12-310001708527us-gaap:AdditionalPaidInCapitalMember2020-12-310001708527us-gaap:CommonClassBMemberus-gaap:CommonStockMember2022-12-310001708527us-gaap:CommonClassAMemberus-gaap:CommonStockMember2022-12-310001708527us-gaap:CommonClassBMemberus-gaap:CommonStockMember2021-12-310001708527us-gaap:CommonClassAMemberus-gaap:CommonStockMember2021-12-310001708527us-gaap:CommonClassBMemberus-gaap:CommonStockMember2020-12-310001708527us-gaap:CommonClassAMemberus-gaap:CommonStockMember2020-12-310001708527azyo:StockOptionPlan2020Member2021-12-310001708527azyo:StockOptionPlan2020Member2021-01-012021-12-310001708527srt:ChiefExecutiveOfficerMemberus-gaap:EmployeeStockOptionMember2022-06-212022-06-210001708527azyo:StockOptionPlan2020Member2022-01-012022-12-310001708527us-gaap:EmployeeStockMember2022-12-310001708527azyo:PerformanceBasedOptionsMember2022-01-012022-12-310001708527us-gaap:EmployeeStockOptionMember2021-01-012021-12-310001708527srt:MinimumMemberus-gaap:EmployeeStockOptionMember2022-01-012022-12-310001708527srt:MaximumMemberus-gaap:EmployeeStockOptionMember2022-01-012022-12-310001708527us-gaap:RestrictedStockUnitsRSUMemberazyo:StockOptionPlan2020Member2022-12-310001708527azyo:PerformanceRestrictedStockUnitMember2022-12-310001708527us-gaap:RestrictedStockUnitsRSUMemberazyo:StockOptionPlan2020Member2021-12-310001708527srt:ChiefExecutiveOfficerMemberus-gaap:RestrictedStockUnitsRSUMember2022-06-212022-06-210001708527azyo:PerformanceRestrictedStockUnitMember2022-01-012022-12-310001708527us-gaap:RestrictedStockUnitsRSUMemberazyo:StockOptionPlan2020Member2022-01-012022-12-310001708527srt:ChiefExecutiveOfficerMemberazyo:TimeBasedRsuMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2022-06-212022-06-210001708527srt:ChiefExecutiveOfficerMemberazyo:TimeBasedRsuMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2022-06-212022-06-210001708527srt:ChiefExecutiveOfficerMemberazyo:TimeBasedOptionsMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2022-06-212022-06-210001708527srt:ChiefExecutiveOfficerMemberazyo:TimeBasedOptionsMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2022-06-212022-06-210001708527srt:MinimumMemberus-gaap:RestrictedStockUnitsRSUMember2022-01-012022-12-310001708527srt:MinimumMemberazyo:PerformanceRestrictedStockUnitMember2022-01-012022-12-310001708527srt:MaximumMemberus-gaap:RestrictedStockUnitsRSUMember2022-01-012022-12-310001708527srt:MaximumMemberazyo:PerformanceRestrictedStockUnitMember2022-01-012022-12-310001708527us-gaap:ShippingAndHandlingMember2022-01-012022-12-310001708527us-gaap:ShippingAndHandlingMember2021-01-012021-12-310001708527us-gaap:PrivatePlacementMember2022-12-080001708527us-gaap:CommonClassAMember2022-12-010001708527us-gaap:CommonClassBMemberus-gaap:PrivatePlacementMember2022-12-082022-12-080001708527us-gaap:CommonClassAMemberus-gaap:PrivatePlacementMember2022-12-082022-12-080001708527us-gaap:PrivatePlacementMember2022-12-082022-12-080001708527azyo:LicenseAgreementWithCookBiotechMember2021-01-012021-12-310001708527us-gaap:UnsecuredDebtMember2022-08-102022-08-100001708527srt:MinimumMemberus-gaap:OfficeEquipmentMember2022-01-012022-12-310001708527srt:MinimumMemberazyo:ProcessingAndResearchEquipmentMember2022-01-012022-12-310001708527srt:MaximumMemberus-gaap:OfficeEquipmentMember2022-01-012022-12-310001708527srt:MaximumMemberazyo:ProcessingAndResearchEquipmentMember2022-01-012022-12-310001708527us-gaap:ComputerEquipmentMember2022-01-012022-12-310001708527us-gaap:CommonClassAMember2022-12-012022-12-010001708527azyo:PaycheckProtectionProgramLoanCaresActMember2020-05-012020-05-310001708527azyo:MidcapLoanFacilityMember2019-07-012019-07-310001708527azyo:MidcapLoanFacilityMember2018-02-012018-02-280001708527azyo:MidcapLoanFacilityMember2017-12-012017-12-310001708527us-gaap:IPOMember2022-01-012022-12-310001708527us-gaap:PrivatePlacementMember2021-01-012021-12-310001708527srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2021-12-310001708527us-gaap:RetainedEarningsMember2022-01-012022-12-310001708527us-gaap:RetainedEarningsMember2021-01-012021-12-310001708527azyo:FibercelStrictLiabilityClaimsForDefectiveDesignDefectiveManufactureAndFailureToWarnMemberstpr:FL2022-01-012022-12-310001708527azyo:FibercelLossOfConsortiumMemberstpr:DE2022-01-012022-12-310001708527azyo:FibercelLitigationProductLabilityNegligenceBreachOfExpressAndImpliedWarrantiesAndPunitiveDamagesMemberstpr:IN2022-01-012022-12-310001708527azyo:NewAssetBasedRevolvingLoanFacilityMember2022-08-100001708527azyo:MidcapLoanFacilityMember2019-07-310001708527us-gaap:UnsecuredDebtMember2022-01-012022-12-310001708527azyo:May2017FinancingMember2022-01-012022-12-310001708527azyo:PaycheckProtectionProgramLoanCaresActMember2021-09-012021-09-300001708527us-gaap:CustomerRelationshipsMember2022-01-012022-12-310001708527azyo:AcquiredProductsMember2022-01-012022-12-310001708527us-gaap:CustomerRelationshipsMember2022-12-310001708527azyo:AcquiredProductsMember2022-12-310001708527us-gaap:CustomerRelationshipsMember2021-12-310001708527azyo:AcquiredProductsMember2021-12-310001708527us-gaap:FairValueInputsLevel3Memberazyo:RevenueInterestObligationMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001708527us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001708527azyo:RevenueInterestObligationMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001708527us-gaap:FairValueMeasurementsRecurringMember2022-12-310001708527us-gaap:FairValueInputsLevel3Memberazyo:RevenueInterestObligationMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001708527us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001708527azyo:RevenueInterestObligationMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001708527us-gaap:FairValueMeasurementsRecurringMember2021-12-310001708527azyo:RevenueInterestObligationMember2022-12-310001708527azyo:RevenueInterestObligationMember2021-12-310001708527azyo:RevenueInterestObligationMember2020-12-310001708527us-gaap:EmployeeStockOptionMemberazyo:StockOptionPlan2020Member2022-01-012022-12-310001708527us-gaap:EmployeeStockOptionMemberazyo:StockOptionPlan2020Member2022-12-310001708527us-gaap:RestrictedStockUnitsRSUMember2022-12-310001708527azyo:SWKLoanFacilityMember2023-11-082023-11-080001708527azyo:MidcapCreditFacilityMember2022-08-102022-08-100001708527us-gaap:DiscontinuedOperationsHeldforsaleMemberazyo:OrthobiologicsBusinessMember2023-09-172023-09-170001708527azyo:MidcapCreditFacilityMember2017-05-310001708527azyo:SWKLoanFacilityMember2022-08-102022-12-310001708527azyo:MidcapCreditFacilityMember2022-08-012022-08-090001708527azyo:MidcapCreditFacilityMember2022-07-012022-07-310001708527azyo:MidcapCreditFacilityMember2022-01-012022-06-300001708527azyo:MidcapLoanFacilityMember2021-01-012022-08-090001708527azyo:MidcapCreditFacilityMember2021-01-012021-12-310001708527us-gaap:UnsecuredDebtMember2017-12-310001708527azyo:MidcapLoanFacilityMember2017-05-310001708527azyo:TermLoanFacilityMember2022-12-310001708527srt:MinimumMemberazyo:SWKLoanFacilityMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember2022-08-102022-08-100001708527azyo:MidcapLoanFacilityMemberus-gaap:LondonInterbankOfferedRateLIBORMember2017-05-312017-05-310001708527azyo:MidcapCreditFacilityMemberus-gaap:LondonInterbankOfferedRateLIBORMember2017-05-312017-05-310001708527azyo:SurgalignHoldingsIncMemberazyo:ViboneExclusivityAgreementMember2018-08-310001708527us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberazyo:ViboneExclusivityAgreementMember2022-01-012022-12-310001708527us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberazyo:ViboneExclusivityAgreementMember2021-01-012021-12-310001708527us-gaap:CommonClassBMember2022-12-310001708527us-gaap:CommonClassAMember2022-12-310001708527us-gaap:CommonClassBMember2021-12-310001708527us-gaap:CommonClassAMember2021-12-310001708527azyo:StockOptionPlan2020Member2022-12-310001708527azyo:StockOptionPlan2020Member2020-10-0700017085272020-12-310001708527us-gaap:CustomerRelationshipsMember2017-05-310001708527azyo:AcquiredProductsMember2017-05-310001708527us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-12-310001708527us-gaap:EmployeeStockOptionMember2022-01-012022-12-310001708527azyo:ClassCommonStockWarrantsMember2022-01-012022-12-310001708527us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-12-310001708527us-gaap:EmployeeStockOptionMember2021-01-012021-12-310001708527us-gaap:SellingAndMarketingExpenseMember2022-01-012022-12-310001708527us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-12-310001708527us-gaap:GeneralAndAdministrativeExpenseMember2022-01-012022-12-310001708527us-gaap:CostOfSalesMember2022-01-012022-12-310001708527us-gaap:SellingAndMarketingExpenseMember2021-01-012021-12-310001708527us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-12-310001708527us-gaap:GeneralAndAdministrativeExpenseMember2021-01-012021-12-310001708527us-gaap:CostOfSalesMember2021-01-012021-12-310001708527us-gaap:AdditionalPaidInCapitalMember2022-01-012022-12-310001708527us-gaap:AdditionalPaidInCapitalMember2021-01-012021-12-310001708527us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberazyo:ViboneExclusivityAgreementMember2022-12-310001708527us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberazyo:ViboneExclusivityAgreementMember2021-12-310001708527srt:MaximumMemberazyo:SWKLoanFacilityMember2022-08-102022-08-100001708527srt:ChiefExecutiveOfficerMemberazyo:PerformanceRestrictedStockUnitMember2022-06-212022-06-210001708527srt:ChiefExecutiveOfficerMemberazyo:PerformanceBasedOptionsMember2022-06-212022-06-210001708527srt:ChiefExecutiveOfficerMemberus-gaap:RestrictedStockUnitsRSUMember2022-06-210001708527srt:ChiefExecutiveOfficerMemberus-gaap:EmployeeStockOptionMember2022-06-210001708527srt:ChiefExecutiveOfficerMemberazyo:TimeBasedOptionsMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2022-06-210001708527us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-12-310001708527us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-12-310001708527azyo:SWKLoanFacilityMember2023-11-080001708527azyo:LigandPharmaceuticalsMember2017-05-012017-05-310001708527azyo:LigandPharmaceuticalsMemberazyo:WhenCumulativeSalesOfProductsExceed300.0Member2017-05-310001708527azyo:LigandPharmaceuticalsMemberazyo:WhenCumulativeSalesOfProductsExceed100.0Member2017-05-310001708527azyo:LigandPharmaceuticalsMember2017-05-310001708527azyo:LigandPharmaceuticalsMember2017-05-312017-05-310001708527srt:MinimumMember2022-01-012022-12-310001708527srt:MaximumMember2022-01-012022-12-310001708527us-gaap:OfficeEquipmentMember2022-12-310001708527us-gaap:LeaseholdImprovementsMember2022-12-310001708527us-gaap:ComputerEquipmentMember2022-12-310001708527azyo:ProcessingAndResearchEquipmentMember2022-12-310001708527us-gaap:OfficeEquipmentMember2021-12-310001708527us-gaap:LeaseholdImprovementsMember2021-12-310001708527us-gaap:ComputerEquipmentMember2021-12-310001708527azyo:ProcessingAndResearchEquipmentMember2021-12-310001708527azyo:LicenseAgreementWithCookBiotechMember2022-01-012022-12-310001708527azyo:LicenseAgreementWithCookBiotechMember2022-12-310001708527us-gaap:StateAndLocalJurisdictionMember2022-12-310001708527us-gaap:DomesticCountryMember2022-12-310001708527azyo:FibercelLitigationProductLabilityMember2022-12-310001708527azyo:ProductionFacilitiesMember2022-12-310001708527azyo:AdministrativeFacilityMember2022-12-310001708527azyo:AdministrativeAndResearchFacilityMember2022-12-310001708527azyo:RevenueInterestObligationMember2021-01-012021-12-310001708527azyo:WomenSHealthMember2022-01-012022-12-310001708527azyo:DeviceProtectionMember2022-01-012022-12-310001708527azyo:CardiovascularMember2022-01-012022-12-310001708527azyo:WomenSHealthMember2021-01-012021-12-310001708527azyo:DeviceProtectionMember2021-01-012021-12-310001708527azyo:CardiovascularMember2021-01-012021-12-310001708527us-gaap:OtherNonoperatingIncomeExpenseMember2022-01-012022-12-310001708527azyo:RevenueInterestObligationMember2022-01-012022-12-310001708527us-gaap:EmployeeStockOptionMember2022-01-012022-12-310001708527azyo:FormerPresidentAndChiefExecutiveOfficerMember2022-09-302022-09-300001708527srt:ChiefExecutiveOfficerMember2022-06-212022-06-210001708527us-gaap:EmployeeStockMember2022-01-012022-12-310001708527azyo:KeralinkInternationalMember2018-01-012018-12-310001708527us-gaap:DiscontinuedOperationsHeldforsaleMemberazyo:OrthobiologicsBusinessMember2022-01-012022-12-310001708527us-gaap:DiscontinuedOperationsHeldforsaleMemberazyo:OrthobiologicsBusinessMember2021-01-012021-12-310001708527us-gaap:DiscontinuedOperationsHeldforsaleMemberazyo:OrthobiologicsBusinessMember2021-12-310001708527us-gaap:DiscontinuedOperationsHeldforsaleMemberazyo:OrthobiologicsBusinessMember2022-12-310001708527us-gaap:DiscontinuedOperationsHeldforsaleMemberazyo:OrthobiologicsBusinessMember2023-09-1700017085272022-01-012022-12-3100017085272021-01-012021-12-3100017085272022-12-3100017085272021-12-310001708527azyo:SWKLoanFacilityMember2022-12-310001708527azyo:SWKLoanFacilityMember2022-08-100001708527azyo:MidcapLoanFacilityMember2022-08-102022-08-100001708527azyo:MidcapLoanFacilityMember2017-05-312017-05-310001708527azyo:SWKLoanFacilityMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember2022-08-102022-08-100001708527azyo:SWKLoanFacilityMember2022-08-102022-08-100001708527azyo:FibercelLitigationProductLabilityMember2022-01-012022-12-310001708527azyo:KeralinkInternationalMember2021-05-310001708527azyo:KeralinkInternationalMember2018-12-31iso4217:USDazyo:casexbrli:purexbrli:sharesiso4217:USDxbrli:sharesazyo:segment UNITED STATES 0001708527false00017085272023-11-202023-11-200001708527us-gaap:AdditionalPaidInCapitalMemberus-gaap:IPOMember2022-01-012022-12-310001708527us-gaap:AdditionalPaidInCapitalMemberus-gaap:PrivatePlacementMember2021-01-012021-12-310001708527us-gaap:CommonClassAMemberus-gaap:CommonStockMemberus-gaap:IPOMember2022-01-012022-12-310001708527us-gaap:CommonClassBMemberus-gaap:CommonStockMemberus-gaap:PrivatePlacementMember2021-01-012021-12-310001708527us-gaap:CommonClassAMemberus-gaap:CommonStockMemberus-gaap:PrivatePlacementMember2021-01-012021-12-310001708527us-gaap:CommonClassAMemberus-gaap:CommonStockMember2022-01-012022-12-310001708527us-gaap:CommonClassAMemberus-gaap:CommonStockMember2021-01-012021-12-310001708527us-gaap:RetainedEarningsMember2022-12-310001708527us-gaap:AdditionalPaidInCapitalMember2022-12-310001708527us-gaap:RetainedEarningsMember2021-12-310001708527us-gaap:AdditionalPaidInCapitalMember2021-12-310001708527us-gaap:RetainedEarningsMember2020-12-310001708527us-gaap:AdditionalPaidInCapitalMember2020-12-310001708527us-gaap:CommonClassBMemberus-gaap:CommonStockMember2022-12-310001708527us-gaap:CommonClassAMemberus-gaap:CommonStockMember2022-12-310001708527us-gaap:CommonClassBMemberus-gaap:CommonStockMember2021-12-310001708527us-gaap:CommonClassAMemberus-gaap:CommonStockMember2021-12-310001708527us-gaap:CommonClassBMemberus-gaap:CommonStockMember2020-12-310001708527us-gaap:CommonClassAMemberus-gaap:CommonStockMember2020-12-310001708527azyo:StockOptionPlan2020Member2021-12-310001708527azyo:StockOptionPlan2020Member2021-01-012021-12-310001708527srt:ChiefExecutiveOfficerMemberus-gaap:EmployeeStockOptionMember2022-06-212022-06-210001708527azyo:StockOptionPlan2020Member2022-01-012022-12-310001708527us-gaap:EmployeeStockMember2022-12-310001708527azyo:PerformanceBasedOptionsMember2022-01-012022-12-310001708527us-gaap:EmployeeStockOptionMember2021-01-012021-12-310001708527srt:MinimumMemberus-gaap:EmployeeStockOptionMember2022-01-012022-12-310001708527srt:MaximumMemberus-gaap:EmployeeStockOptionMember2022-01-012022-12-310001708527us-gaap:RestrictedStockUnitsRSUMemberazyo:StockOptionPlan2020Member2022-12-310001708527azyo:PerformanceRestrictedStockUnitMember2022-12-310001708527us-gaap:RestrictedStockUnitsRSUMemberazyo:StockOptionPlan2020Member2021-12-310001708527srt:ChiefExecutiveOfficerMemberus-gaap:RestrictedStockUnitsRSUMember2022-06-212022-06-210001708527azyo:PerformanceRestrictedStockUnitMember2022-01-012022-12-310001708527us-gaap:RestrictedStockUnitsRSUMemberazyo:StockOptionPlan2020Member2022-01-012022-12-310001708527srt:ChiefExecutiveOfficerMemberazyo:TimeBasedRsuMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2022-06-212022-06-210001708527srt:ChiefExecutiveOfficerMemberazyo:TimeBasedRsuMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2022-06-212022-06-210001708527srt:ChiefExecutiveOfficerMemberazyo:TimeBasedOptionsMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2022-06-212022-06-210001708527srt:ChiefExecutiveOfficerMemberazyo:TimeBasedOptionsMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2022-06-212022-06-210001708527srt:MinimumMemberus-gaap:RestrictedStockUnitsRSUMember2022-01-012022-12-310001708527srt:MinimumMemberazyo:PerformanceRestrictedStockUnitMember2022-01-012022-12-310001708527srt:MaximumMemberus-gaap:RestrictedStockUnitsRSUMember2022-01-012022-12-310001708527srt:MaximumMemberazyo:PerformanceRestrictedStockUnitMember2022-01-012022-12-310001708527us-gaap:ShippingAndHandlingMember2022-01-012022-12-310001708527us-gaap:ShippingAndHandlingMember2021-01-012021-12-310001708527us-gaap:PrivatePlacementMember2022-12-080001708527us-gaap:CommonClassAMember2022-12-010001708527us-gaap:CommonClassBMemberus-gaap:PrivatePlacementMember2022-12-082022-12-080001708527us-gaap:CommonClassAMemberus-gaap:PrivatePlacementMember2022-12-082022-12-080001708527us-gaap:PrivatePlacementMember2022-12-082022-12-080001708527azyo:LicenseAgreementWithCookBiotechMember2021-01-012021-12-310001708527us-gaap:UnsecuredDebtMember2022-08-102022-08-100001708527srt:MinimumMemberus-gaap:OfficeEquipmentMember2022-01-012022-12-310001708527srt:MinimumMemberazyo:ProcessingAndResearchEquipmentMember2022-01-012022-12-310001708527srt:MaximumMemberus-gaap:OfficeEquipmentMember2022-01-012022-12-310001708527srt:MaximumMemberazyo:ProcessingAndResearchEquipmentMember2022-01-012022-12-310001708527us-gaap:ComputerEquipmentMember2022-01-012022-12-310001708527us-gaap:CommonClassAMember2022-12-012022-12-010001708527azyo:PaycheckProtectionProgramLoanCaresActMember2020-05-012020-05-310001708527azyo:MidcapLoanFacilityMember2019-07-012019-07-310001708527azyo:MidcapLoanFacilityMember2018-02-012018-02-280001708527azyo:MidcapLoanFacilityMember2017-12-012017-12-310001708527us-gaap:IPOMember2022-01-012022-12-310001708527us-gaap:PrivatePlacementMember2021-01-012021-12-310001708527srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2021-12-310001708527us-gaap:RetainedEarningsMember2022-01-012022-12-310001708527us-gaap:RetainedEarningsMember2021-01-012021-12-310001708527azyo:FibercelStrictLiabilityClaimsForDefectiveDesignDefectiveManufactureAndFailureToWarnMemberstpr:FL2022-01-012022-12-310001708527azyo:FibercelLossOfConsortiumMemberstpr:DE2022-01-012022-12-310001708527azyo:FibercelLitigationProductLabilityNegligenceBreachOfExpressAndImpliedWarrantiesAndPunitiveDamagesMemberstpr:IN2022-01-012022-12-310001708527azyo:NewAssetBasedRevolvingLoanFacilityMember2022-08-100001708527azyo:MidcapLoanFacilityMember2019-07-310001708527us-gaap:UnsecuredDebtMember2022-01-012022-12-310001708527azyo:May2017FinancingMember2022-01-012022-12-310001708527azyo:PaycheckProtectionProgramLoanCaresActMember2021-09-012021-09-300001708527us-gaap:CustomerRelationshipsMember2022-01-012022-12-310001708527azyo:AcquiredProductsMember2022-01-012022-12-310001708527us-gaap:CustomerRelationshipsMember2022-12-310001708527azyo:AcquiredProductsMember2022-12-310001708527us-gaap:CustomerRelationshipsMember2021-12-310001708527azyo:AcquiredProductsMember2021-12-310001708527us-gaap:FairValueInputsLevel3Memberazyo:RevenueInterestObligationMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001708527us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001708527azyo:RevenueInterestObligationMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001708527us-gaap:FairValueMeasurementsRecurringMember2022-12-310001708527us-gaap:FairValueInputsLevel3Memberazyo:RevenueInterestObligationMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001708527us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001708527azyo:RevenueInterestObligationMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001708527us-gaap:FairValueMeasurementsRecurringMember2021-12-310001708527azyo:RevenueInterestObligationMember2022-12-310001708527azyo:RevenueInterestObligationMember2021-12-310001708527azyo:RevenueInterestObligationMember2020-12-310001708527us-gaap:EmployeeStockOptionMemberazyo:StockOptionPlan2020Member2022-01-012022-12-310001708527us-gaap:EmployeeStockOptionMemberazyo:StockOptionPlan2020Member2022-12-310001708527us-gaap:RestrictedStockUnitsRSUMember2022-12-310001708527azyo:SWKLoanFacilityMember2023-11-082023-11-080001708527azyo:MidcapCreditFacilityMember2022-08-102022-08-100001708527us-gaap:DiscontinuedOperationsHeldforsaleMemberazyo:OrthobiologicsBusinessMember2023-09-172023-09-170001708527azyo:MidcapCreditFacilityMember2017-05-310001708527azyo:SWKLoanFacilityMember2022-08-102022-12-310001708527azyo:MidcapCreditFacilityMember2022-08-012022-08-090001708527azyo:MidcapCreditFacilityMember2022-07-012022-07-310001708527azyo:MidcapCreditFacilityMember2022-01-012022-06-300001708527azyo:MidcapLoanFacilityMember2021-01-012022-08-090001708527azyo:MidcapCreditFacilityMember2021-01-012021-12-310001708527us-gaap:UnsecuredDebtMember2017-12-310001708527azyo:MidcapLoanFacilityMember2017-05-310001708527azyo:TermLoanFacilityMember2022-12-310001708527srt:MinimumMemberazyo:SWKLoanFacilityMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember2022-08-102022-08-100001708527azyo:MidcapLoanFacilityMemberus-gaap:LondonInterbankOfferedRateLIBORMember2017-05-312017-05-310001708527azyo:MidcapCreditFacilityMemberus-gaap:LondonInterbankOfferedRateLIBORMember2017-05-312017-05-310001708527azyo:SurgalignHoldingsIncMemberazyo:ViboneExclusivityAgreementMember2018-08-310001708527us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberazyo:ViboneExclusivityAgreementMember2022-01-012022-12-310001708527us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberazyo:ViboneExclusivityAgreementMember2021-01-012021-12-310001708527us-gaap:CommonClassBMember2022-12-310001708527us-gaap:CommonClassAMember2022-12-310001708527us-gaap:CommonClassBMember2021-12-310001708527us-gaap:CommonClassAMember2021-12-310001708527azyo:StockOptionPlan2020Member2022-12-310001708527azyo:StockOptionPlan2020Member2020-10-0700017085272020-12-310001708527us-gaap:CustomerRelationshipsMember2017-05-310001708527azyo:AcquiredProductsMember2017-05-310001708527us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-12-310001708527us-gaap:EmployeeStockOptionMember2022-01-012022-12-310001708527azyo:ClassCommonStockWarrantsMember2022-01-012022-12-310001708527us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-12-310001708527us-gaap:EmployeeStockOptionMember2021-01-012021-12-310001708527us-gaap:SellingAndMarketingExpenseMember2022-01-012022-12-310001708527us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-12-310001708527us-gaap:GeneralAndAdministrativeExpenseMember2022-01-012022-12-310001708527us-gaap:CostOfSalesMember2022-01-012022-12-310001708527us-gaap:SellingAndMarketingExpenseMember2021-01-012021-12-310001708527us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-12-310001708527us-gaap:GeneralAndAdministrativeExpenseMember2021-01-012021-12-310001708527us-gaap:CostOfSalesMember2021-01-012021-12-310001708527us-gaap:AdditionalPaidInCapitalMember2022-01-012022-12-310001708527us-gaap:AdditionalPaidInCapitalMember2021-01-012021-12-310001708527us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberazyo:ViboneExclusivityAgreementMember2022-12-310001708527us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberazyo:ViboneExclusivityAgreementMember2021-12-310001708527srt:MaximumMemberazyo:SWKLoanFacilityMember2022-08-102022-08-100001708527srt:ChiefExecutiveOfficerMemberazyo:PerformanceRestrictedStockUnitMember2022-06-212022-06-210001708527srt:ChiefExecutiveOfficerMemberazyo:PerformanceBasedOptionsMember2022-06-212022-06-210001708527srt:ChiefExecutiveOfficerMemberus-gaap:RestrictedStockUnitsRSUMember2022-06-210001708527srt:ChiefExecutiveOfficerMemberus-gaap:EmployeeStockOptionMember2022-06-210001708527srt:ChiefExecutiveOfficerMemberazyo:TimeBasedOptionsMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2022-06-210001708527us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-12-310001708527us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-12-310001708527azyo:SWKLoanFacilityMember2023-11-080001708527azyo:LigandPharmaceuticalsMember2017-05-012017-05-310001708527azyo:LigandPharmaceuticalsMemberazyo:WhenCumulativeSalesOfProductsExceed300.0Member2017-05-310001708527azyo:LigandPharmaceuticalsMemberazyo:WhenCumulativeSalesOfProductsExceed100.0Member2017-05-310001708527azyo:LigandPharmaceuticalsMember2017-05-310001708527azyo:LigandPharmaceuticalsMember2017-05-312017-05-310001708527srt:MinimumMember2022-01-012022-12-310001708527srt:MaximumMember2022-01-012022-12-310001708527us-gaap:OfficeEquipmentMember2022-12-310001708527us-gaap:LeaseholdImprovementsMember2022-12-310001708527us-gaap:ComputerEquipmentMember2022-12-310001708527azyo:ProcessingAndResearchEquipmentMember2022-12-310001708527us-gaap:OfficeEquipmentMember2021-12-310001708527us-gaap:LeaseholdImprovementsMember2021-12-310001708527us-gaap:ComputerEquipmentMember2021-12-310001708527azyo:ProcessingAndResearchEquipmentMember2021-12-310001708527azyo:LicenseAgreementWithCookBiotechMember2022-01-012022-12-310001708527azyo:LicenseAgreementWithCookBiotechMember2022-12-310001708527us-gaap:StateAndLocalJurisdictionMember2022-12-310001708527us-gaap:DomesticCountryMember2022-12-310001708527azyo:FibercelLitigationProductLabilityMember2022-12-310001708527azyo:ProductionFacilitiesMember2022-12-310001708527azyo:AdministrativeFacilityMember2022-12-310001708527azyo:AdministrativeAndResearchFacilityMember2022-12-310001708527azyo:RevenueInterestObligationMember2021-01-012021-12-310001708527azyo:WomenSHealthMember2022-01-012022-12-310001708527azyo:DeviceProtectionMember2022-01-012022-12-310001708527azyo:CardiovascularMember2022-01-012022-12-310001708527azyo:WomenSHealthMember2021-01-012021-12-310001708527azyo:DeviceProtectionMember2021-01-012021-12-310001708527azyo:CardiovascularMember2021-01-012021-12-310001708527us-gaap:OtherNonoperatingIncomeExpenseMember2022-01-012022-12-310001708527azyo:RevenueInterestObligationMember2022-01-012022-12-310001708527us-gaap:EmployeeStockOptionMember2022-01-012022-12-310001708527azyo:FormerPresidentAndChiefExecutiveOfficerMember2022-09-302022-09-300001708527srt:ChiefExecutiveOfficerMember2022-06-212022-06-210001708527us-gaap:EmployeeStockMember2022-01-012022-12-310001708527azyo:KeralinkInternationalMember2018-01-012018-12-310001708527us-gaap:DiscontinuedOperationsHeldforsaleMemberazyo:OrthobiologicsBusinessMember2022-01-012022-12-310001708527us-gaap:DiscontinuedOperationsHeldforsaleMemberazyo:OrthobiologicsBusinessMember2021-01-012021-12-310001708527us-gaap:DiscontinuedOperationsHeldforsaleMemberazyo:OrthobiologicsBusinessMember2021-12-310001708527us-gaap:DiscontinuedOperationsHeldforsaleMemberazyo:OrthobiologicsBusinessMember2022-12-310001708527us-gaap:DiscontinuedOperationsHeldforsaleMemberazyo:OrthobiologicsBusinessMember2023-09-1700017085272022-01-012022-12-3100017085272021-01-012021-12-3100017085272022-12-3100017085272021-12-310001708527azyo:SWKLoanFacilityMember2022-12-310001708527azyo:SWKLoanFacilityMember2022-08-100001708527azyo:MidcapLoanFacilityMember2022-08-102022-08-100001708527azyo:MidcapLoanFacilityMember2017-05-312017-05-310001708527azyo:SWKLoanFacilityMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember2022-08-102022-08-100001708527azyo:SWKLoanFacilityMember2022-08-102022-08-100001708527azyo:FibercelLitigationProductLabilityMember2022-01-012022-12-310001708527azyo:KeralinkInternationalMember2021-05-310001708527azyo:KeralinkInternationalMember2018-12-31iso4217:USDazyo:casexbrli:purexbrli:sharesiso4217:USDxbrli:sharesazyo:segment UNITED STATES Pursuant to Section 13 or 15(d) of the Securities Exchange [...]

(EDGAR Online via COMTEX) -- Filed Pursuant to Rule 424(b)(3) Registration No. 333-268613 Prospectus Supplement No. 4 (To Prospectus dated February 10, 2023) Filed Pursuant to Rule 424(b)(3) Registration No. [...]

(EDGAR Online via COMTEX) -- Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations Caution: This discussion and analysis may contain predictions, estimates and other forward-looking [...]

(EDGAR Online via COMTEX) -- Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations The following discussion and analysis and the unaudited interim financial statements included [...]

(EDGAR Online via COMTEX) -- 0000886163false00008861632023-11-082023-11-08 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ______________ FORM 8-K ______________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities [...]

(EDGAR Online via COMTEX) -- 0001636651false00016366512023-11-032023-11-03 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION [...]

(EDGAR Online via COMTEX) -- Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations The following information should be read in conjunction with our unaudited condensed [...]

(EDGAR Online via COMTEX) -- 0000886163false00008861632023-10-182023-10-18 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ______________ FORM 8-K ______________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities [...]

(EDGAR Online via COMTEX) -- 0001636651false00016366512023-10-172023-10-17 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION [...]

(EDGAR Online via COMTEX) -- 0000886163false00008861632023-09-182023-09-18 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ______________ FORM 8-K ______________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities [...]

(EDGAR Online via COMTEX) -- false000146715400014671542023-08-312023-08-31 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act [...]

(EDGAR Online via COMTEX) -- false000146715400014671542023-07-142023-07-14 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act [...]

(EDGAR Online via COMTEX) -- Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations The following discussion and analysis and the unaudited interim financial statements included [...]

(EDGAR Online via COMTEX) -- Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations Caution: This discussion and analysis may contain predictions, estimates and other forward-looking [...]

(EDGAR Online via COMTEX) -- 0000886163false00008861632023-05-042023-05-04 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ______________ FORM 8-K ______________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities [...]

(EDGAR Online via COMTEX) -- Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations This Quarterly Report on Form 10-Q contains 'forward-looking statements' as defined in [...]

(EDGAR Online via COMTEX) -- Filed Pursuant to Rule 424(b)(3) Registration No. 333-268613 Prospectus Supplement No. 1 (To Prospectus dated February 10, 2023) [[Image Removed: image_0a.jpg]] OmniAb, Inc. [[Image Removed: [...]

(EDGAR Online via COMTEX) -- FALSE000184625300018462532023-03-302023-03-300001846253us-gaap:CommonStockMember2023-03-302023-03-300001846253us-gaap:WarrantMember2023-03-302023-03-30 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ______________ FORM 8-K ______________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities [...]

(EDGAR Online via COMTEX) -- 0000886163false00008861632023-03-132023-03-13 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ______________ FORM 8-K ______________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities [...]

(EDGAR Online via COMTEX) -- 0000886163false00008861632023-02-222023-02-22 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ______________ FORM 8-K ______________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities [...]

(EDGAR Online via COMTEX) -- NASDAQ NASDAQ false 0001846253 0001846253 2022-11-15 2022-11-15 0001846253 us-gaap:CommonStockMember 2022-11-15 2022-11-15 0001846253 us-gaap:WarrantMember 2022-11-15 2022-11-15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM [...]